Saturn V Capital Management LLC Apellis Pharmaceuticals, Inc. Transaction History

Saturn V Capital Management LLC

  • $265 Billion
  • Q2 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024
SELL
$55.39 - $72.47 $3.96 Million - $5.18 Million
-71,464 Reduced 50.0%
71,463 $4.2 Billion
Q4 2023

Feb 14, 2024
BUY
$37.14 - $64.82 $5.31 Million - $9.26 Million
142,927 New
142,927 $8.56 Billion
Q2 2023

Aug 14, 2023
SELL
$76.68 - $93.31 $1.21 Million - $1.47 Million
-15,759 Reduced 12.8%
107,406 $9.78 Billion
Q1 2023

May 15, 2023
SELL
$46.59 - $66.96 $4.15 Million - $5.97 Million
-89,164 Reduced 41.99%
123,165 $8.12 Billion
Q4 2022

Feb 09, 2023
BUY
$43.24 - $61.04 $9.18 Million - $13 Million
212,329 New
212,329 $9.41 Billion

Others Institutions Holding APLS

# of Institutions
299
Shares Held
113M
Call Options Held
5.21M
Put Options Held
691K
View Full List

About Apellis Pharmaceuticals, Inc.

APLS Quotes by TradingView
  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $4.51B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Saturn V Capital Management LLC Portfolio

Follow Saturn V Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Saturn V Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Saturn V Capital Management LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email